(NASDAQ: RVMD) Revolution Medicines's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.01%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.01%.
Revolution Medicines's earnings in 2026 is -$960,978,000.On average, 22 Wall Street analysts forecast RVMD's earnings for 2026 to be -$1,307,769,817, with the lowest RVMD earnings forecast at -$1,464,474,851, and the highest RVMD earnings forecast at -$1,025,078,266. On average, 16 Wall Street analysts forecast RVMD's earnings for 2027 to be -$1,172,677,937, with the lowest RVMD earnings forecast at -$1,606,564,907, and the highest RVMD earnings forecast at -$261,851,676.
In 2028, RVMD is forecast to generate -$693,882,776 in earnings, with the lowest earnings forecast at -$1,451,213,112 and the highest earnings forecast at $383,643,153.